Arvest Bank Trust Division Exits Position in Eli Lilly and Co (LLY)

Eli Lilly and Co (LLY) : Arvest Bank Trust Division has sold out all of its stake in Eli Lilly and Co during the most recent quarter, according to the disclosure filed by the company on Oct 7, 2016 with the SEC. The investment management company has sold out 3,292 shares of Eli Lilly and Co which is valued at $270,240.

Other Hedge Funds, Including , Exxonmobil Investment Management Inc Tx reduced its stake in LLY by selling 3,413 shares or 1.36% in the most recent quarter. The Hedge Fund company now holds 248,028 shares of LLY which is valued at $20,360,619. Eli Lilly and Co makes up approx 0.43% of Exxonmobil Investment Management Inc Tx’s portfolio.Indiana Trust Investment Management Co boosted its stake in LLY in the latest quarter, The investment management firm added 155 additional shares and now holds a total of 10,815 shares of Eli Lilly and Co which is valued at $884,126. Eli Lilly and Co makes up approx 0.46% of Indiana Trust Investment Management Co’s portfolio. New England Research Management sold out all of its stake in LLY during the most recent quarter. The investment firm sold 7,400 shares of LLY which is valued $604,950.Lvm Capital Management Ltdmi boosted its stake in LLY in the latest quarter, The investment management firm added 15,326 additional shares and now holds a total of 63,265 shares of Eli Lilly and Co which is valued at $5,171,914. Eli Lilly and Co makes up approx 1.63% of Lvm Capital Management Ltdmi’s portfolio.

Eli Lilly and Co opened for trading at $81.57 and hit $82.31 on the upside on Friday, eventually ending the session at $82.09, with a gain of 0.76% or 0.62 points. The heightened volatility saw the trading volume jump to 42,41,408 shares. Company has a market cap of $90,615 M.

On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.

Many Wall Street Analysts have commented on Eli Lilly and Co. Eli Lilly and Co was Upgraded by Goldman to ” Buy” on Sep 27, 2016. Eli Lilly and Co was Upgraded by JP Morgan to ” Overweight” on Sep 8, 2016.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.